Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 06.08.2021 | 07:00

Carl Zeiss Meditec records significant increase in revenue and raises annual targets

DGAP-News: Carl Zeiss Meditec AG / Key word(s): 9 Month figures/Quarterly / Interim Statement
06.08.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec records significant increase in revenue and raises annual targets
 
Acceleration of growth in both strategic business units with good contributions from all reporting regions
 

JENA, 6 August 2021

Carl Zeiss Meditec generated revenue of €1,198.2m in the first nine months of fiscal year 2020/21 (prior year: €967.9m), growing by +23.8% (adjusted for currency effects: +27.6%). Earnings before interest and taxes (EBIT) increased overproportionally, to €282.8m (prior year: €111.9m). The EBIT margin was 23.6% (prior year: 11.6%).

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG: "Our business is making an increasingly perceptible recovery from the effects of the COVID-19 pandemic. In addition to the renewed strong growth in recurring revenue, we also achieved further progress in our equipment business."

All strategic business units contribute to growth

Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by +30.2% in the first nine months of fiscal year 2020/21 (adjusted for currency effects: +33.9%), to €923.4m (prior year: €709.1m). In particular, the business with recurring revenue from consumables, implants and services made a significant contribution to this growth. The recovery of revenue continued in the strategic business unit Microsurgery; there was an acceleration in the third quarter in particular. Revenue increased by +6.2% in the first nine months (adjusted for currency effects: +10.4%), to €274.8m (prior year: €258.7m).

High growth rates in all reporting regions

Revenue in the EMEA[1] region increased by +18.0% (adjusted for currency effects: +19.8%), to €317.3m (prior year: €268.8m). Once again, there was a positive trend in the markets of Germany, France and Southern Europe, and the UK.

Revenue in the Americas region increased by a further +12.3%, to €305.9m, due to the further acceleration in the US business (prior year: €272.3m) - adjusted for currency effects, revenue increased by +21.0%.

Once again, the APAC[2] region made the strongest contribution to growth. Revenue increased by 34.7% (adjusted for currency effects: +36.7%) to €575.0m (prior year: €426.8m). China and South Korea had the highest growth rates.

Significant increase in operating result year-on-year

The operating result (earnings before interest and taxes: EBIT) increased disproportionately in the first nine months of fiscal year 2020/21, to €282.8m (prior year: €111.9m). This was driven in particular by a favorable product mix and a high proportion of recurring revenue, as well as low selling and marketing expenses. The EBIT margin increased to 23.6% (prior year: 11.6%). Adjusted for special effects, this resulted in an increase to 23.9% (prior year: 12.1%). Earnings per share increased to €2.04 (prior year: €0.77).

Due to the positive development of business, the Company has raised its targets for the current fiscal year 2020/21. Revenue is expected to exceed the previous target of around €1.6bn (prior year: €1,335.5bn). The EBIT margin is expected to significantly exceed the previous target of around 20% in fiscal year 2020/21 (prior year: 13.3%), bolstered to a great extent by the current low selling and marketing expenses.


Revenue by strategic business unit

All figures in €m      9 Months
2020/21
     9 Months
2019/20
     Change from
prior year
     Change from prior year
(currency-adjusted)
Ophthalmic Devices     923.4 709.1 +30.2 +33.9
Microsurgery 274.8 258.7 +6.2 +10.4
Consolidated 1,198.2 967.9 +23.8 +27.6%
 

Revenue by region

All figures in €m                  9 Months
2020/21
     9 Months
2019/20
    Change from
prior year
     Change from prior year
(currency-adjusted)
EMEA 317.3 268.8 +18.0 +19.8
Americas 305.9 272.3 +12.3 +21.0
APAC 575.0 426.8 +34.7 +36.7
Consolidated 1,198.2 967.9 +23.8 +27.6%
 

Further information on our publication and the Analyst Conference Call on the results for the first nine months of fiscal year 2020/21 can be found at
https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

 

Contact for investors and press

Sebastian Frericks
Head of Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.de/presse

[1] Europe/Middle East/Africa
[2] Asia/Pacific



06.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021